Elanco Animal Health (ELAN) Stock Forecast, Price Target & Predictions
ELAN Stock Forecast
Elanco Animal Health stock forecast is as follows: an average price target of $26.50 (represents a 97.17% upside from ELAN’s last price of $13.44) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
ELAN Price Target
The average price target for Elanco Animal Health (ELAN) is $26.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $37.00 to $16.00. This represents a potential 97.17% upside from ELAN's last price of $13.44.
ELAN Analyst Ratings
According to 5 Wall Street analysts, Elanco Animal Health's rating consensus is 'Buy'. The analyst rating breakdown for ELAN stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 1 'Hold' (20.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).
Elanco Animal Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 23, 2024 | Balaji Prasad | Barclays | $22.00 | $14.07 | 56.36% | 63.69% |
| Jul 01, 2024 | David Westenberg | Piper Sandler | $16.00 | $14.43 | 10.88% | 19.05% |
| May 13, 2024 | David Westenberg | Piper Sandler | $19.00 | $17.00 | 11.76% | 41.37% |
| Mar 12, 2024 | David Westenberg | Piper Sandler | $18.00 | $15.77 | 14.14% | 33.93% |
| Jan 05, 2024 | Jonathan Block | Stifel Nicolaus | $20.00 | $15.45 | 29.45% | 48.81% |
| Sep 12, 2022 | - | Barclays | $18.00 | $15.00 | 20.00% | 33.93% |
| Aug 16, 2022 | David Westenberg | Piper Sandler | $21.00 | $19.08 | 10.06% | 56.25% |
| Jul 18, 2022 | - | J.P. Morgan | $32.00 | $20.14 | 58.89% | 138.10% |
| Jun 24, 2022 | - | Stifel Nicolaus | $22.00 | $19.94 | 10.33% | 63.69% |
| May 19, 2022 | - | Goldman Sachs | $32.00 | $23.35 | 37.04% | 138.10% |
The latest Elanco Animal Health stock forecast, released on Sep 23, 2024 by Balaji Prasad from Barclays, set a price target of $22.00, which represents a 56.36% increase from the stock price at the time of the forecast ($14.07), and a 63.69% increase from ELAN last price ($13.44).
Elanco Animal Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 5 |
| Avg Price Target | - | $22.00 | $19.00 |
| Last Closing Price | $13.44 | $13.44 | $13.44 |
| Upside/Downside | -100.00% | 63.69% | 41.37% |
In the current month, the average price target of Elanco Animal Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Elanco Animal Health's last price of $13.44. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 28, 2024 | Morgan Stanley | Buy | Buy | Hold |
| Sep 23, 2024 | Barclays | Overweight | Overweight | Hold |
| Sep 20, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Sep 19, 2024 | Piper Sandler | Buy | Buy | Hold |
| Sep 19, 2024 | Morgan Stanley | Underperform | Underperform | Hold |
| Sep 19, 2024 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| Jul 01, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| May 13, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| May 09, 2024 | Bank of America Securities | Buy | Buy | Hold |
| May 09, 2024 | Barclays | Overweight | Overweight | Hold |
Elanco Animal Health's last stock rating was published by Morgan Stanley on Oct 28, 2024. The company gave ELAN a "Buy" rating, the same as its previous rate.
Elanco Animal Health Financial Forecast
Elanco Animal Health Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.07B | $1.06B | $1.26B | $988.00M | $1.03B | $1.18B | $1.23B | $1.11B | $1.13B | $1.28B | $1.24B | $1.14B | $889.60M | $586.30M | $657.70M | $787.00M | $771.30M |
| Avg Forecast | $1.10B | $1.13B | $1.24B | $1.27B | $1.07B | $1.08B | $1.18B | $1.21B | $1.01B | $1.04B | $1.15B | $1.19B | $1.00B | $1.04B | $1.04B | $1.19B | $980.94M | $1.03B | $1.18B | $1.22B | $1.10B | $1.08B | $1.24B | $1.16B | $1.05B | $913.80M | $575.44M | $721.62M | $790.45M | $764.69M |
| High Forecast | $1.11B | $1.14B | $1.24B | $1.28B | $1.07B | $1.09B | $1.19B | $1.22B | $1.02B | $1.05B | $1.15B | $1.19B | $1.01B | $1.04B | $1.04B | $1.20B | $987.68M | $1.03B | $1.18B | $1.22B | $1.10B | $1.08B | $1.24B | $1.16B | $1.05B | $913.80M | $575.44M | $721.62M | $790.45M | $764.69M |
| Low Forecast | $1.10B | $1.12B | $1.23B | $1.27B | $1.06B | $1.08B | $1.17B | $1.20B | $1.01B | $1.03B | $1.15B | $1.18B | $988.87M | $1.04B | $1.03B | $1.19B | $975.97M | $1.03B | $1.18B | $1.22B | $1.10B | $1.08B | $1.24B | $1.16B | $1.05B | $913.80M | $575.44M | $721.62M | $790.45M | $764.69M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 6 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 9 | 9 | 9 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.02% | 1.05% | 1.01% | 1.00% | 1.00% | 1.01% | 1.01% | 1.05% | 1.03% | 1.07% | 1.08% | 0.97% | 1.02% | 0.91% | 1.00% | 1.01% |
Elanco Animal Health's average Quarter revenue forecast for Dec 23 based on 7 analysts is $1.00B, with a low forecast of $988.87M, and a high forecast of $1.01B. ELAN's average Quarter revenue forecast represents a -6.21% decrease compared to the company's last Quarter revenue of $1.07B (Sep 23).
Elanco Animal Health EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 6 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 9 | 9 | 9 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $42.00M | $166.00M | $346.00M | $136.00M | $211.00M | $268.00M | $345.00M | $108.00M | $100.00M | $-6.00M | $183.00M | $-35.50M | $-28.60M | $28.60M | $30.20M | $97.80M | $84.90M |
| Avg Forecast | $79.52M | $81.49M | $89.27M | $92.11M | $76.96M | $78.32M | $85.27M | $87.61M | $73.14M | $74.87M | $82.94M | $351.45M | $72.37M | $75.11M | $74.97M | $319.50M | $90.85M | $188.14M | $214.61M | $290.46M | $201.16M | $197.23M | $226.36M | $78.77M | $192.24M | $166.54M | $104.88M | $39.64M | $144.06M | $139.37M |
| High Forecast | $80.06M | $82.05M | $89.88M | $92.75M | $77.49M | $78.86M | $85.85M | $88.33M | $73.87M | $75.58M | $82.94M | $421.74M | $73.11M | $75.18M | $75.48M | $383.40M | $109.02M | $188.14M | $214.61M | $348.55M | $201.16M | $197.23M | $226.36M | $94.52M | $192.24M | $166.54M | $104.88M | $47.56M | $144.06M | $139.37M |
| Low Forecast | $79.11M | $81.08M | $88.82M | $91.65M | $76.57M | $77.93M | $84.83M | $86.89M | $72.77M | $74.16M | $82.94M | $281.16M | $71.44M | $75.03M | $74.59M | $255.60M | $72.68M | $188.14M | $214.61M | $232.37M | $201.16M | $197.23M | $226.36M | $63.02M | $192.24M | $166.54M | $104.88M | $31.71M | $144.06M | $139.37M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.56% | 2.21% | 1.08% | 1.50% | 1.12% | 1.25% | 1.19% | 0.54% | 0.51% | -0.03% | 2.32% | -0.18% | -0.17% | 0.27% | 0.76% | 0.68% | 0.61% |
7 analysts predict ELAN's average Quarter EBITDA for Dec 23 to be $72.37M, with a high of $73.11M and a low of $71.44M. This is 72.30% upper than Elanco Animal Health's previous annual EBITDA (Sep 23) of $42.00M.
Elanco Animal Health Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 6 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 9 | 9 | 9 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.10B | $-97.00M | $103.00M | $-54.00M | $-49.00M | $-22.00M | $48.00M | $-97.00M | $-104.00M | $-210.00M | $-61.00M | $-322.80M | $-135.00M | $-53.20M | $-49.10M | $-9.50M | $10.00M |
| Avg Forecast | $94.56M | $79.63M | $151.80M | $179.17M | $90.58M | $75.86M | $136.86M | $152.68M | $76.44M | $60.92M | $119.29M | $56.42M | $52.03M | $62.03M | $23.43M | $51.29M | $-81.59M | $78.39M | $124.66M | $46.63M | $83.20M | $81.70M | $132.68M | $-26.26M | $48.79M | $59.80M | $18.46M | $-64.44M | $112.45M | $126.68M |
| High Forecast | $95.41M | $80.34M | $153.15M | $180.77M | $91.38M | $76.54M | $138.08M | $162.23M | $81.54M | $61.47M | $119.37M | $67.70M | $67.64M | $63.43M | $23.63M | $61.55M | $-65.28M | $78.39M | $124.66M | $55.95M | $83.20M | $81.70M | $132.68M | $-21.01M | $48.79M | $59.80M | $18.46M | $-51.55M | $112.45M | $126.68M |
| Low Forecast | $93.94M | $79.11M | $150.80M | $177.99M | $89.98M | $75.37M | $135.96M | $147.91M | $71.35M | $60.52M | $119.21M | $45.14M | $41.62M | $60.63M | $23.27M | $41.03M | $-97.91M | $78.39M | $124.66M | $37.30M | $83.20M | $81.70M | $132.68M | $-31.51M | $48.79M | $59.80M | $18.46M | $-77.33M | $112.45M | $126.68M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.67% | -4.14% | 2.01% | 0.66% | -0.63% | -0.18% | 1.03% | -1.17% | -1.27% | -1.58% | 2.32% | -6.62% | -2.26% | -2.88% | 0.76% | -0.08% | 0.08% |
Elanco Animal Health's average Quarter net income forecast for Jun 23 is $23.43M, with a range of $23.27M to $23.63M. ELAN's average Quarter net income forecast represents a -77.26% decrease compared to the company's last Quarter net income of $103.00M (Mar 23).
Elanco Animal Health SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 6 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 9 | 9 | 9 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $313.00M | $353.00M | $327.00M | $303.00M | $298.00M | $343.00M | $320.00M | $329.00M | $342.00M | $385.00M | $348.00M | $374.10M | $277.70M | $162.80M | $364.00M | $237.30M | $243.00M |
| Avg Forecast | $313.48M | $321.27M | $351.93M | $363.14M | $303.41M | $308.78M | $336.15M | $345.39M | $288.35M | $295.16M | $326.97M | $376.14M | $285.29M | $296.10M | $295.55M | $341.94M | $276.75M | $294.02M | $335.38M | $310.86M | $314.37M | $308.22M | $353.76M | $149.79M | $300.43M | $260.27M | $163.90M | $477.75M | $225.14M | $217.80M |
| High Forecast | $315.64M | $323.48M | $354.35M | $365.64M | $305.49M | $310.90M | $338.46M | $348.24M | $291.21M | $297.96M | $326.97M | $451.36M | $288.22M | $296.39M | $297.58M | $410.33M | $332.10M | $294.02M | $335.38M | $373.03M | $314.37M | $308.22M | $353.76M | $179.75M | $300.43M | $260.27M | $163.90M | $573.30M | $225.14M | $217.80M |
| Low Forecast | $311.90M | $319.65M | $350.15M | $361.30M | $301.87M | $307.21M | $334.44M | $342.53M | $286.89M | $292.37M | $326.97M | $300.91M | $281.66M | $295.81M | $294.05M | $273.55M | $221.40M | $294.02M | $335.38M | $248.69M | $314.37M | $308.22M | $353.76M | $119.83M | $300.43M | $260.27M | $163.90M | $382.20M | $225.14M | $217.80M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.19% | 0.96% | 1.09% | 1.01% | 1.02% | 1.03% | 1.05% | 1.11% | 1.09% | 2.32% | 1.25% | 1.07% | 0.99% | 0.76% | 1.05% | 1.12% |
Elanco Animal Health's average Quarter SG&A projection for Dec 23 is $285.29M, based on 7 Wall Street analysts, with a range of $281.66M to $288.22M. The forecast indicates a -8.85% fall compared to ELAN last annual SG&A of $313.00M (Sep 23).
Elanco Animal Health EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 6 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 9 | 9 | 9 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-2.22 | $-0.20 | $0.21 | $-0.11 | $-0.10 | $-0.04 | $0.10 | $-0.20 | $-0.21 | $-0.43 | $-0.12 | $-0.66 | $-0.29 | $-0.13 | $-0.12 | $-0.03 | $0.03 |
| Avg Forecast | $0.19 | $0.16 | $0.30 | $0.36 | $0.18 | $0.15 | $0.27 | $0.31 | $0.15 | $0.12 | $0.24 | $0.27 | $0.10 | $0.12 | $0.05 | $0.29 | $0.13 | $0.16 | $0.25 | $0.35 | $0.17 | $0.17 | $0.27 | $0.23 | $0.10 | $0.12 | $0.04 | $0.24 | $0.23 | $0.26 |
| High Forecast | $0.19 | $0.16 | $0.31 | $0.36 | $0.18 | $0.15 | $0.28 | $0.33 | $0.16 | $0.12 | $0.24 | $0.28 | $0.14 | $0.13 | $0.05 | $0.29 | $0.13 | $0.16 | $0.25 | $0.35 | $0.17 | $0.17 | $0.27 | $0.23 | $0.10 | $0.12 | $0.04 | $0.24 | $0.23 | $0.26 |
| Low Forecast | $0.19 | $0.16 | $0.30 | $0.36 | $0.18 | $0.15 | $0.27 | $0.30 | $0.14 | $0.12 | $0.24 | $0.27 | $0.08 | $0.12 | $0.05 | $0.28 | $0.13 | $0.16 | $0.25 | $0.35 | $0.17 | $0.17 | $0.27 | $0.23 | $0.10 | $0.12 | $0.04 | $0.24 | $0.23 | $0.26 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.81% | -4.25% | 0.74% | -0.86% | -0.63% | -0.18% | 0.28% | -1.19% | -1.27% | -1.60% | -0.53% | -6.68% | -2.40% | -3.48% | -0.51% | -0.13% | 0.12% |
According to 6 Wall Street analysts, Elanco Animal Health's projected average Quarter EPS for Jun 23 is $0.05, with a low estimate of $0.05 and a high estimate of $0.05. This represents a -77.59% decrease compared to ELAN previous annual EPS of $0.21 (Mar 23).
Elanco Animal Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ESPR | Esperion Therapeutics | $2.41 | $16.00 | 563.90% | Buy |
| IRWD | Ironwood Pharmaceuticals | $3.52 | $11.67 | 231.53% | Buy |
| PCRX | Pacira BioSciences | $17.03 | $35.00 | 105.52% | Hold |
| ELAN | Elanco Animal Health | $13.44 | $26.50 | 97.17% | Buy |
| LNTH | Lantheus | $86.45 | $146.25 | 69.17% | Buy |
| COLL | Collegium Pharmaceutical | $30.00 | $40.50 | 35.00% | Buy |
| ALKS | Alkermes | $27.91 | $36.38 | 30.35% | Hold |
| CTLT | Catalent | $59.00 | $74.25 | 25.85% | Hold |
| TEVA | Teva Pharmaceutical Industries | $17.03 | $20.00 | 17.44% | Buy |
| ITCI | Intra-Cellular Therapies | $85.64 | $94.50 | 10.35% | Buy |
| PBH | Prestige Consumer Healthcare | $82.67 | $89.50 | 8.26% | Buy |
| VTRS | Viatris | $13.13 | $13.75 | 4.72% | Hold |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| HLN | Haleon | $9.48 | $9.15 | -3.48% | Buy |
| PAHC | Phibro Animal Health | $23.39 | $18.67 | -20.18% | Buy |